Drug Profile
SCB 1019
Alternative Names: RSV F antigen vaccine; SCB-1019Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Clover Biopharmaceuticals
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 08 Apr 2024 Immunogenicity and adverse events data from a phase I trial in Respiratory syncytial virus infections, were released by Clover Biopharmaceuticals
- 13 Dec 2023 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in Australia (Parentral)
- 10 Jul 2023 Clover Biopharmaceuticals announces intension to disclose development plans for SCB 1019, in H2 2023